A Proof of Concept and Open-label Study to Test the Efficacy and Safety of Pasireotide in Patients With Ectopic ACTH-producing Tumors
Latest Information Update: 17 Sep 2021
Price :
$35 *
At a glance
- Drugs Pasireotide (Primary)
- Indications Cushing syndrome
- Focus Proof of concept; Therapeutic Use
- 26 Jan 2018 Status changed from recruiting to withdrawn prior to enrolment.
- 07 Jun 2016 New trial record